FORTRESS BIOTECH, INC.

Consensus Fortress Biotech, Inc.

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-07 EDT			5-day change	1st Jan Change
2.040 ^USD	-0.49%		-7.27%	-44.26%

08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Evolution of the Average Target: Fortress Biotech, Inc.

Evolution of the Average Target - Fortress Biotech, Inc.

Evolution of the Target Price: Fortress Biotech, Inc.

Evolution of the Target Price - Fortress Biotech, Inc.

Changes in Analyst Recommendations: Fortress Biotech, Inc.

ffc4135a7de0bdb568078a3df3.-X6jpcqu7T9TROsIlGYFWP1hP8uQjMQJuo8A-dZIK0Q.lEju3IeDt0oDA4xZ9xxhMIoEapinyZ1O9b9TvrdwRDbKCeXBgO-ocBV9jA~0a36a2d0858af68552d83299d1cc4a61

Analysts' recommendations: Fortress Biotech, Inc.

25-10-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
25-10-01	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
25-10-01	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
24-03-19	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
23-11-29	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT
23-08-22	B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Fortress Biotech to $5 From $6, Maintains Overweight Rating	MT
22-08-04	Ladenburg Thalmann Starts Fortress Biotech at Buy With $6 Price Target	MT
22-07-14	B. Riley Securities Lowers Fortress Biotech's Price Target to $6 from $8, Keeps Buy Rating	MT
22-03-29	Benchmark Capital Adjusts Fortress Biotech's Price Target to $5 from $8, Keeps Buy Rating	MT
21-06-17	Fortress Biotech : B. Riley Lowers Fortress Biotech's PT to $8 from $9, Says Incremental Pipeline Updates Suggest Heightened Focus on Next-Gen Therapies; Keeps Buy Rating	MT
21-04-20	Fortress Biotech : Roth Capital Adjusts Price Target on Fortress Biotech to $5 From $4.50, Maintains Buy Rating	MT
21-04-05	Fortress Biotech : B. Riley Raises Fortress Biotech's Price Target to $9 from $8 After 'Strong' Q4 2020 Results, Keeps Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	FORTRESS BIOTECH, INC.			-	-	+143.9%
	ELI LILLY AND COMPANY					+14.8%
	JOHNSON & JOHNSON					+9.76%
	ABBVIE INC.					+5.1%
	MERCK & CO., INC.					+10.16%
	ROCHE HOLDING AG					+7.39%
	NOVARTIS AG					+7.01%
	ASTRAZENECA PLC					+32.09%
	AMGEN INC.					-2.92%
	GILEAD SCIENCES, INC.					+10%
	Average					+23.73%
	Weighted average by Cap.					+10.94%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

2.050USD

Average target price

5.000USD

Spread / Average Target

+143.90%

High Price Target

5.000USD

Spread / Highest target

+143.90%

Low Price Target

5.000USD

Spread / Lowest Target

+143.90%

Analyst Consensus Detail

Analyst consensus - Fortress Biotech, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Fortress Biotech, Inc.

Stock Market
Stocks
FBIO Stock
Consensus Fortress Biotech, Inc.

As early as today, start finding the best investment opportunities!